Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome
Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome
Active, not recruiting · NCT06856759 · Registry updated 2026-05-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Rett syndrome, X-linked disease, hereditary disease, inherited neurodegenerative disorder, intellectual disability, nervous system disorder | Active, not recruiting | Early phase 1 | 2026-05-28 | NCT06856759 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Women and Children's Medical Center | 43 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Guangzhou Women and Children's Medical Center | Guangzhou | China | 14 |